EMERGENT BIOSOLUTIONS INC. COMMON STOCK

Emergent BioSolutions Awarded Procurement Contract Valued up to $235.8 Million to Supply BioThrax® (Anthrax Vaccine Adsorbed) to the U.S. Department of Defense

11 يناير 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Emergent BioSolutions to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 11, 2024

09 يناير 2024 06:30:00 بحسب Nasdaq GlobeNewswire

Emergent BioSolutions Receives $75 Million Contract Option from BARDA to Procure Doses of CYFENDUS™ (Anthrax Vaccine Adsorbed, Adjuvanted)

28 نوفمبر 2023 05:59:00 بحسب Nasdaq GlobeNewswire

Emergent BioSolutions Receives NYSE Notice Regarding Delayed Form 10-Q Filing

24 نوفمبر 2023 06:30:00 بحسب Nasdaq GlobeNewswire

Emergent BioSolutions Reports Third Quarter 2023 Financial Results

08 نوفمبر 2023 16:38:16 بحسب Nasdaq GlobeNewswire

UPDATE: Emergent BioSolutions to Release Third Quarter 2023 Financial Results and Conduct Conference Call on November 8, 2023

30 أكتوبر 2023 15:45:13 بحسب Nasdaq GlobeNewswire

Emergent BioSolutions to Release Third Quarter 2023 Financial Results and Conduct Conference Call on November 2, 2023

19 أكتوبر 2023 05:30:00 بحسب Nasdaq GlobeNewswire

Emergent BioSolutions Names Two Pharmaceutical Industry Veterans to Board of Directors

02 أكتوبر 2023 06:00:00 بحسب Nasdaq GlobeNewswire

Emergent BioSolutions’ NARCAN® Nasal Spray Launches Over the Counter Making it Possible for Everyone to Help Save a Life from an Opioid Overdose Emergency

30 أغسطس 2023 04:59:00 بحسب Nasdaq GlobeNewswire

Emergent BioSolutions Reports Financial Results for Second Quarter 2023

08 أغسطس 2023 15:31:58 بحسب Nasdaq GlobeNewswire

Emergent BioSolutions Announces Strategic Steps to Strengthen Core Business and Financial Position

08 أغسطس 2023 06:15:00 بحسب Nasdaq GlobeNewswire

Emergent BioSolutions Awarded 10-Year BARDA Contract Valued at up to a Maximum of $704 Million for Advanced Development and Procurement of Ebanga™ Treatment for Ebola

31 يوليو 2023 15:05:00 بحسب Nasdaq GlobeNewswire

Emergent BioSolutions Receives U.S. FDA Approval of CYFENDUS™ (Anthrax Vaccine Adsorbed, Adjuvanted), previously known as AV7909, a Two-Dose Anthrax Vaccine for Post-Exposure Prophylaxis Use

20 يوليو 2023 17:03:20 بحسب Nasdaq GlobeNewswire

Emergent BioSolutions Announces CEO Transition

27 يونيو 2023 06:55:00 بحسب Nasdaq GlobeNewswire

Emergent BioSolutions Finalizes Sale of Travel Health Business to Bavarian Nordic

15 مايو 2023 06:58:00 بحسب Nasdaq GlobeNewswire

Emergent BioSolutions to Hold Virtual Annual Meeting of Stockholders on Thursday, May 25, 2023 at 9:00am EDT

11 مايو 2023 05:30:00 بحسب Nasdaq GlobeNewswire

Emergent BioSolutions Reports Financial Results For First Quarter 2023

09 مايو 2023 15:05:02 بحسب Nasdaq GlobeNewswire

Emergent BioSolutions to Release First Quarter 2023 Financial Results and Conduct Conference Call on May 9, 2023

19 أبريل 2023 15:05:00 بحسب Nasdaq GlobeNewswire

U.S. FDA Approves Over-the-Counter Designation for Emergent BioSolutions’ NARCAN® Nasal Spray, a Historic Milestone for the Opioid Overdose Emergency Treatment

29 مارس 2023 08:48:20 بحسب Nasdaq GlobeNewswire

Emergent BioSolutions Reports Financial Results for Fourth Quarter 2022

27 فبراير 2023 15:42:44 بحسب Nasdaq GlobeNewswire